TORONTO, March 26 /PRNewswire-FirstCall/ - Spectral today announces the presentation of positive data concerning the use of the Endotoxin Activity Assay (EAA(TM)) at the 27th Annual International Symposium of Critical Care and Emergency Medicine, March 27-30, Brussels, Belgium.
Dr John Marshall, Professor of Medicine, and current president of the International Sepsis Forum will present a plenary lecture entitled "Endotoxemia in the Critically Ill".
"Spectral's EAA(TM) assay, the only world-wide regulatory approved assay for endotoxin in the blood stream, continues to gain acceptance from the presentation of the results of our multiple clinical studies, performed by leading critical care doctors," stated Dr. Paul Walker, President and CEO. "Increased levels of endotoxin seem to play a significant role in a number of different disease processes," continued Dr. Walker.
Spectral is a developer of innovative technologies for comprehensive disease management. Spectral provides accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Current products include Spectral's FDA approved rapid diagnostic for West Nile Virus (RapidWN(TM)) and its FDA approved rapid diagnostic for sepsis (EAA(TM)) as well as a range of other biological reagents. Spectral's common shares are listed on The Toronto Stock Exchange under the symbol SDI.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
Spectral Diagnostics Inc.CONTACT: At: Spectral Diagnostics Inc., Dr. Paul Walker, Chief ExecutiveOfficer, (416) 626-3233
